| 2026-03-30 |
股东大会：
将于2026-05-07召开股东大会
会议内容 ▼▲
- 1.Directors are elected by a plurality of the votes cast, with the nominees obtaining the most votes cast being elected. Votes that are withheld and broker non-votes, if any, are not counted as votes cast and will have no effect on the outcome of the proposal.
2.This proposal must be approved by a majority of the votes cast on the matter. As a result, abstentions and broker non-votes, if any, will have no effect on the outcome of the proposal.
3.This non-binding, advisory proposal must be approved by a majority of the votes cast on the matter. As a result, abstentions and broker non-votes, if any, will have no effect on the outcome of the proposal.
|
| 2026-03-27 |
详情>>
内部人交易：
QUAY STEVEN C股份增加65000.00股
|
| 2026-03-25 |
详情>>
股本变动：
变动后总股本861.14万股
|
| 2026-03-25 |
详情>>
业绩披露：
2025年年报每股收益-4.04美元,归母净利润-3477万美元,同比去年增长-36.33%
|
| 2026-01-31 |
复牌提示：
2026-01-30 19:50:00 停牌，复牌日期 2026-02-02 09:00:00
|
| 2026-01-26 |
详情>>
拆分方案：
每15.0000合并分成1.0000股
|
| 2025-12-22 |
股东大会：
将于2026-01-20召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our Certificate of Incorporation to effect a reverse stock split of our common stock at a reverse stock split ratio ranging from 5:1 to 20:1, inclusive (“Proposal 1”);
2.To approve an adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies (“Proposal 2”);
3.To transact any other matters that may properly come before the Special Meeting or any adjournments or postponements thereof.
|
| 2025-11-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.18美元,归母净利润-2383.3万美元,同比去年增长-24.41%
|
| 2025-08-12 |
详情>>
业绩披露：
2025年中报每股收益-0.12美元,归母净利润-1514.1万美元,同比去年增长-26.95%
|
| 2025-05-13 |
详情>>
业绩披露：
2025年一季报每股收益-0.05美元,归母净利润-671.8万美元,同比去年增长-14.29%
|
| 2025-03-26 |
股东大会：
将于2025-05-08召开股东大会
会议内容 ▼▲
- 1.Election of Class I directors. Directors are elected by a plurality of the votes cast, with the nominees obtaining the most votes cast being elected. Votes that are withheld and broker non-votes, if any, are not counted as votes cast and will have no effect on the outcome of the proposal.
2.Ratification of the selection of the independent registered public accounting firm. This proposal must be approved by a majority of the votes cast on the matter. As a result, abstentions and broker non-votes, if any, will have no effect on the outcome of the proposal.
3.Approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers. This non-binding, advisory proposal must be approved by a majority of the votes cast on the matter. As a result, abstentions and broker non-votes, if any, will have no effect on the outcome of the proposal.
4.An advisory vote to determine the frequency of future advisory votes on the compensation of the Company’s named executive officers. This non-binding, advisory proposal must be approved by a majority of the votes cast on the matter. As a result, abstentions and broker non-votes, if any, will have no effect on the outcome of the proposal.
|
| 2025-03-25 |
详情>>
业绩披露：
2024年年报每股收益-0.2美元,归母净利润-2550.4万美元,同比去年增长15.25%
|
| 2025-03-25 |
财报披露：
美东时间 2025-03-25 盘前发布财报
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.15美元,归母净利润-1915.7万美元,同比去年增长14.25%
|
| 2024-08-12 |
详情>>
业绩披露：
2024年中报每股收益-0.1美元,归母净利润-1192.7万美元,同比去年增长25.97%
|
| 2024-05-23 |
股东大会：
将于2024-06-27召开股东大会
会议内容 ▼▲
- 1.The election of the two Class III director nominees named in the Proxy Statement;
2.The ratification of the selection of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.The approval of an amendment and restatement of the Company’s 2020 Stock Incentive Plan, as amended, to increase the shares available for issuance by 12,000,000 shares and to extend the term thereof;
4.The approval of an amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock from 175,000,000 to 350,000,000;
5.The approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers;
6.The transaction of any other business that may properly come before the meeting or any adjournment or postponement thereof.
|
| 2024-05-13 |
详情>>
业绩披露：
2024年一季报每股收益-0.05美元,归母净利润-587.8万美元,同比去年增长6.42%
|
| 2024-04-01 |
详情>>
业绩披露：
2023年年报每股收益-0.24美元,归母净利润-3009.4万美元,同比去年增长-11.62%
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.18美元,归母净利润-2234万美元,同比去年增长-14.75%
|
| 2023-03-30 |
股东大会：
将于2023-05-04召开股东大会
会议内容 ▼▲
- 1.Election of directors
2.Ratification of selection of independent registered public accounting firm.
3.Advisory (non-binding) vote to approve executive compensation.
|
| 2022-04-11 |
股东大会：
将于2022-05-13召开股东大会
会议内容 ▼▲
- 1.Election of directors
2.Ratification of selection of independent registered public accounting firm
3.Amendment to the certificate of incorporation to increase the number of authorized shares of common stock by 100,000,000 shares.
4.Advisory vote to approve executive compensation
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-09 |
股东大会：
将于2021-09-07召开股东大会
会议内容 ▼▲
- 1.AMENDMENT TO THE CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK BY 100,000,000 SHARES.
|
| 2021-04-15 |
股东大会：
将于2021-05-14召开股东大会
会议内容 ▼▲
- 1.the election of two Class III directors named in the Proxy Statement;
2.the ratification of the selection of BDO USA LLP (“BDO”) as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3. the approval to increase authorized shares under the Atossa Therapeutics, Inc. 2020 Incentive Plan (the “Plan”) by 15,000,000 shares;
4.approval of an amendment to the certificate of incorporation to increase the number of shares of authorized common stock by 325,000,000 shares;
5.an advisory (non-binding) vote on the Company’s executive compensation;
6.the transaction of any other business that may properly come before the meeting or any adjournment thereof.
|
| 2020-04-13 |
股东大会：
将于2020-05-15召开股东大会
会议内容 ▼▲
- 1.the election of two Class II directors named in the Proxy Statement;
2.the ratification of the selection of BDO USA LLP (“BDO”) as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.the approval of the Atossa Therapeutics, Inc. 2020 Stock Incentive Plan (the “Plan”);
4.an advisory (non-binding) vote on the Company’s executive compensation;
5.the transaction of any other business that may properly come before the meeting or any adjournment thereof.
|
| 2019-04-12 |
股东大会：
将于2019-05-16召开股东大会
会议内容 ▼▲
- 1.Vote by proxy - You may complete, sign and return a proxy card;
2.Vote by attendance - You may attend the annual meeting in person and vote at the meeting.
3.Proxy Vote by Internet - You may use the Internet to transmit your voting instructions up until 9:00 a.m. Pacific Daylight Time on May 16, 2019 by going to the website http://www.AALvote.com/ATOS. Please have your proxy card in hand when you access the website and follow the instructions to obtain your records and to create an electronic voting instruction form.
4.Proxy Vote by Phone - You may use any touch-tone telephone to transmit your voting instructions up until 9:00 a.m. Pacific Daylight Time on May 16, 2019 by calling the toll-free number 1-866-804-9616. Have your proxy card in hand when you call and then follow the instructions.
|
| 2018-04-20 |
详情>>
拆分方案：
每12.0000合并分成1.0000股
|
| 2018-03-20 |
股东大会：
将于2018-04-12召开股东大会
会议内容 ▼▲
- (1) the election of two Class III directors named in the Proxy Statement;
(2) the ratification of the selection of BDO USA LLP (“BDO”) as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
(3) the approval to increase authorized shares under the Atossa Genetics 2010 Stock Option and Incentive Plan (the “Plan”) by 6,000,000 shares;
(4) approval of an amendment (in the event it is deemed by the Board of Directors to be advisable) to the certificate of incorporation to effect a reverse stock split of the issued and outstanding shares of common stock at a ratio within the range of 3:1 up to a split of 15:1, as determined by the Board of Directors;
(5) approval of an amendment to the certificate of incorporation to increase the number of shares of authorized common stock by 100 million;
(6) an advisory (non-binding) vote on the Company’s executive compensation; (7) an advisory (non-binding) vote on the frequency of future advisory votes on executive compensation;
(8) the transaction of any other business that may properly come before the meeting or any adjournment thereof.
|
| 2017-04-13 |
股东大会：
将于2017-05-09召开股东大会
会议内容 ▼▲
- 1.the election of two Class II directors named in the Proxy Statement;
2.the ratification of the selection of BDO USA LLP (“BDO”) as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
3.the approval to increase authorized shares under the Atossa Genetics 2010 Stock Option and Incentive Plan by 1,500,000 shares;
4.the transaction of any other business that may properly come before the meeting or any adjournment thereof.
|
| 2016-08-25 |
详情>>
拆分方案：
每15.0000合并分成1.0000股
|
| 2016-04-13 |
股东大会：
将于2016-05-18召开股东大会
会议内容 ▼▲
- 1.Election of directors. Directors are elected by a plurality, with the nominees obtaining the most votes being elected. Because there is no minimum vote required, abstentions and broker non-votes will be entirely excluded from the vote and will have no effect on its outcome.
2.Ratification of selection of independent registered public accounting firm. This proposal must be approved by a majority of the shares present in person or represented by proxy and entitled to vote on the proposal. As a result, abstentions will have the same effect as voting against the proposal and broker non-votes will have no effect on the vote outcome.
3.Approval to increase the authorized shares under the 2010 Stock Option and Incentive plan by 2,000,000 shares. This proposal must be approved by a majority of the shares present in person or represented by proxy and entitled to vote on the proposal. As a result, abstentions will have the same effect as voting against the proposal and broker non-votes will have no effect on the vote outcome.
4.Approval of an amendment to Atossa’s certificate of incorporation to increase the number of authorized shares of common stock by 100,000,000 shares. This proposal must be approved by the affirmative vote of the holders of a majority of the common stock outstanding and entitled to vote on the Record Date. As a result, abstentions and broker non-votes will have the same effect as voting against this proposal.
5.Approval of an amendment to Atossa’s certificate of incorporation to effect a reverse stock split. This proposal must be approved by the affirmative vote of the holders of a majority of the shares of common stock outstanding and entitled to vote on the Record Date. As a result, abstentions and broker non-votes will have the same effect as voting against this proposal.
6.Advisory (non-binding) vote on the compensation of our named executive officers. This proposal must be approved by a majority of the shares present in person or represented by proxy and entitled to vote on the proposal. As a result, abstentions will have the same effect as voting against the proposal and broker non-votes will have no effect on the vote outcome.
|